David M. Evans
Co-founder
pharmaceutical
Sirnaomics
China
Biography
David M. Evans, Ph.D, Co-founder. Dr. Evans has over 20 years experience in drug target and small molecule discovery for oncology, infectious diseases and CNS therapeutics. Dr. Evans has been a pioneer in target/drug discovery technologies including high throughput gene silencing using RNAi. Before joining Sirnaomics, Inc. David served as Sr. Director, RNAi Discovery and Therapeutic Services group, Thermo Fisher Scientific (TFS), Lafayette, CO; Head of Drug Discovery, Cancer Drug Development Lab Translational Genomics Research Institute (TGEN), Gaithersburg, MD; Director, Drug Discovery Psychiatric Genomics Inc., Gaithersburg, MD; and Head, High Throughput Screening for Serono Pharmaceuticals, Boston, MA. Prior to this David was with Millennium Pharmaceuticals, Cambridge, MA. Dr. Evans is the inventor on a number of issued and pending patents, and has been an invited speaker for many international professional conferences and webinars on siRNA screening and drug discovery. He received his BSc (1983) and PhD (1987) from Imperial College, London and has published a number of peer reviewed papers and review articles.
Research Interest
Business, Management, Toxicology, Pharmacology
